DigestRedComo funciona
Red
/
Empresas
Ca
No verificado

Candid Therapeutics, Inc.

Sobre qué escribimos

BiotecnologíaCienciaFarmacéuticaMedicina - VariosSalud

8 Comunicados de prensa

Ver todos los comunicados de prensa
19/09/2025
Salud
Ciencia
Medicina - Varios
Biotecnología
Eventos
Candid Therapeutics Recognized as a 2025 Endpoints 11 Honoree
Fuente
Candid Therapeutics, Inc.
Editor
Business Wire
1.00
0
28/08/2025
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Eventos
Candid Therapeutics to Participate in Investor and Policy Conferences
Fuente
Candid Therapeutics, Inc.
Editor
Business Wire
1.00
0
20/06/2025
Ciencia
Medicina - Varios
Biología
Biotecnología
Salud
Farmacéutica
Sanidad
Oncología
Industria
Candid Therapeutics Advances Portfolio of Novel T-Cell Engagers into Five Autoimmune Diseases for Clinical Evaluation
Fuente
Candid Therapeutics, Inc.
Editor
Business Wire
1.00
0
07/01/2025
Mercado laboral
Biotecnología
Salud
Biología
Farmacéutica
Medicina - Varios
Candid Therapeutics Enters into Agreement with WuXi Biologics on Trispecific T-cell Engager
Fuente
Candid Therapeutics, Inc.
Editor
Business Wire
1.00
0
16/12/2024
Ciencia
Biología
Biotecnología
Farmacéutica
Sanidad
Salud
Medicina - Varios
Mercado laboral
Candid Therapeutics and EpimAb Biotherapeutics Enter Into Research Collaboration to Discover and Develop Novel T-Cell Engagers for Autoimmune Indications
Fuente
Candid Therapeutics, Inc.
Editor
Business Wire
1.00
0
16/12/2024
Mercado laboral
Industria
Biotecnología
VIH, SIDA y enfermedades autoinmunes
Salud
Farmacéutica
Medicina - Varios
Candid Therapeutics and Ab Studio Enter Into Research Collaboration to Discover and Develop Novel T Cell Engagers for Autoimmune Indications
Fuente
Candid Therapeutics, Inc.
Editor
Business Wire
1.00
0
16/10/2024
Mercado laboral
Ciencia
Biología
Biotecnología
Farmacéutica
Sanidad
Salud
Medicina - Varios
Candid Therapeutics Appoints Highly Accomplished Industry Leaders Angie You, Ph.D. and Dan Puckett to it’s Board of Directors
Fuente
Candid Therapeutics, Inc.
Editor
Business Wire
1.00
0
09/09/2024
Biotecnología
Farmacéutica
Salud
Candid Therapeutics Debuts with $370M Capital Raise to Clinically Evaluate Potentially Transformative Autoimmune Therapies
Fuente
Candid Therapeutics, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0